title: [A Case of Renal Cell Carcinoma with Malignant Pleural Effusion Showing Marked Response to Axitinib].
abstract: A 36-year-old woman had undergone left radical nephrectomy followed by interferon-α and sunitinib for the treatment of renal cell carcinoma with para-aortic lymph node and lung involvements (papillary renal cell carcinoma, G3, cT3aN1M1) in the previous hospital. She was referred to our hospital for further treatment and received serial molecular targeted agents (everolimus, sorafenib, sunitinib) and radiation therapy for right ischial and femoral bone metastases. Then she was found to have multiple metastatic lesions in the lungs and carcinomatous pleural effusion associated with dyspnea. After failure of pleurosclerosis with OK-432, the pleural effusion markedly reduced by axitinib administration, but the pleural effusion relapsed a few days after axitinib was discontinued. For this reason, axitinib was maintained in spite of appearance of new metastatic lesions in the brain. The pleural effusion was well-controlled for 16 months but she died of progressive disease, including metastatic lesions in the brain and in the lungs.
authors.affiliation: The Department of Urology, Osaka Medical Center for Cancer and Cardiovascular Diseases.
authors.forename: Yu
authors.initials: Y
authors.lastname: Ishizuya
authors.affiliation: The Department of Urology, Osaka Medical Center for Cancer and Cardiovascular Diseases.
authors.forename: Takuya
authors.initials: T
authors.lastname: Okusa
authors.affiliation: The Department of Urology, Osaka Medical Center for Cancer and Cardiovascular Diseases.
authors.forename: Koji
authors.initials: K
authors.lastname: Hatano
authors.affiliation: The Department of Urology, Osaka Medical Center for Cancer and Cardiovascular Diseases.
authors.forename: Yasutomo
authors.initials: Y
authors.lastname: Nakai
authors.affiliation: The Department of Urology, Osaka Medical Center for Cancer and Cardiovascular Diseases.
authors.forename: Masashi
authors.initials: M
authors.lastname: Nakayama
authors.affiliation: The Department of Urology, Osaka Medical Center for Cancer and Cardiovascular Diseases.
authors.forename: Ken-Ichi
authors.initials: KI
authors.lastname: Kakimoto
authors.affiliation: The Department of Urology, Osaka Medical Center for Cancer and Cardiovascular Diseases.
authors.forename: Kazuo
authors.initials: K
authors.lastname: Nishimura
mesh_terms: D000328:Adult; D000077784:Axitinib; D002292:Carcinoma, Renal Cell / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007191:Indazoles / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000601:surgery; D009392:Nephrectomy; D016066:Pleural Effusion, Malignant / Q000209:etiology*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
chemical_list: D007093:Imidazoles; D007191:Indazoles; D047428:Protein Kinase Inhibitors; D000077784:Axitinib